Compare ATLO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | SLS |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.2M | 706.7M |
| IPO Year | 2001 | 2007 |
| Metric | ATLO | SLS |
|---|---|---|
| Price | $26.35 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 34.7K | ★ 5.4M |
| Earning Date | 04-24-2026 | 04-16-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 8.03 | ★ 62.69 |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.09 | $0.95 |
| 52 Week High | $28.35 | $5.66 |
| Indicator | ATLO | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 69.64 |
| Support Level | $19.47 | $1.48 |
| Resistance Level | $28.28 | N/A |
| Average True Range (ATR) | 0.62 | 0.46 |
| MACD | -0.26 | 0.11 |
| Stochastic Oscillator | 19.14 | 91.10 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.